Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of 225Ac-TR2205 in Triple-negative Breast Cancer
NCT07340424Phase 1Recruiting
- Sponsor
- ACON Laboratories
- Start
- May 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 225Ac-TR2205 in triple-negative breast cancer (TNBC), sponsored by ACON Laboratories. Primary endpoint: Incidence and severity grades of adverse events. Started May 2025; status: recruiting.
02
Drugs
225Ac-TR2205
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07340424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07340424.